ADAP News and Press, Adaptimmune Therapeutics plc From 05/12/23

2023-05-12 13:09:08 ET Adaptimmune Therapeutics plc (ADAP) Q1 2023 Earnings Conference Call May 12, 2023, 08:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, La...

2023-05-12 08:39:11 ET Adaptimmune press release ( NASDAQ: ADAP ): Q1 GAAP EPS of $0.00 beats by $0.14 . Revenue of $47.6M (+1222.2% Y/Y). For further details see: Adaptimmune GAAP EPS of $0.00 beats by $0.14, revenue of $47.6M

2023-05-11 12:11:35 ET Adaptimmune ( NASDAQ: ADAP ) is scheduled to announce Q1 earnings results on Friday, May 12th, before market open. The consensus EPS Estimate is -$0.17 and the consensus Revenue Estimate is $4.6M (+27.8% Y/Y). Over the last 1 year, ADAP has bea...

2023-05-11 11:47:13 ET Major earnings expected before the bell on Friday include: Air Canada ( OTCQX:ACDVF ) Allianz SE ( OTCPK:ALIZF ) Crescent Point Energy ( CPG ) Charlotte's Web Holdings ( OTCQX:CWBHF ) Tata Motors ( TTM ) For further deta...

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the first quarter ended March 31, 2023, before...

2023-04-21 14:24:33 ET Summary ADAP is swapping 1.5117 of its shares for every TCRR share. There is a huge spread between the two values, so existing shareholders can lock in a big gain once the deal closes. The spread is available as an arbitrage (by shorting ADAP) with a few...

2023-04-18 16:37:11 ET Adaptimmune Therapeutics ( NASDAQ: ADAP ) and TCR Therapeutics ( NASDAQ: TCRR ) have set May 30 for shareholder votes on their planned combination. The vote is scheduled for 7:30am EST at the Adaptimmune's ( ADAP ) headquarters in the UK, acc...

2023-04-11 12:13:33 ET Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the rights to Adaptimmune's PRAME and NY-ESO cell therapy...

2023-04-11 09:35:58 ET Adaptimmune Therapeutics ( NASDAQ: ADAP ) said it will regain rights to the PRAME and NY-ESO cell therapy programs from GSK ( NYSE: GSK ). Adaptimmune will receive an upfront payment plus milestone-based payments totaling £30M related t...

- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy - - Adaptimmune and GSK will work collaboratively to ensure continuity for patients in ongoing clinical trials for lete-cel and next generation TCR T-cells targeting NY-ESO - -Adaptimmune will receive £30 ...